A Review of the Role of the Pharmacist in Heart Failure Transition of Care

被引:47
作者
Anderson, Sarah L. [1 ]
Marrs, Joel C. [1 ]
机构
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO 80045 USA
关键词
Cardiology; Care transitions; Healthcare quality; Heart failure; Medication adherence; Medication reconciliation; Medication therapy management; Multidisciplinary care; Patient care team; Sacubitril/valsartan; TEAM-BASED CARE; MEDICATION ADHERENCE; HEALTH LITERACY; SCIENTIFIC STATEMENT; CLINICAL PHARMACIST; AMERICAN-COLLEGE; DISEASE; MANAGEMENT; PATIENT; SERVICE;
D O I
10.1007/s12325-018-0671-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This article reviews current literature on the role of pharmacists in the transition of care (TOC) for patients with heart failure (HF) and the impact of their contributions on therapeutic and economic outcomes. Optimizing the TOC for patients with HF from the hospital to the community/home is crucial for improving outcomes and decreasing high rates of hospital readmissions, which are associated with increased morbidity, mortality, and costs. A multidisciplinary team approach to the management of patients with HF facilitates the transition from the hospital to the ambulatory care setting, allowing for the consideration of medical, pharmacological, and lifestyle variables that impact the care of individual patients. Pharmacist participation on both inpatient and outpatient teams can provide a variety of services that have been shown to reduce hospital readmission rates and benefit patient management and treatment. These include medication reconciliation, patient education, medication dosage titration and adjustment, patient monitoring, development of disease management pathways, promotion of medication adherence, and postdischarge follow-up. In addition, as new pharmacologic treatments for HF become available, pharmacists can raise awareness of optimal drug use by maximizing education related to efficacy (e.g., adherence) and safety (e.g., potential side effects and drug interactions). Improving understanding of HF and its treatment will enable increased pharmacist involvement in the TOC that should lead to improved outcomes and reduced healthcare costs. Funding: Novartis.
引用
收藏
页码:311 / 323
页数:13
相关论文
共 62 条
[1]   Keeping your patient with heart failure safe - A review of potentially dangerous medications [J].
Amabile, CM ;
Spencer, AP .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (07) :709-720
[2]  
American College of Cardiology, QUAL IMPR I H2H
[3]  
American College of Cardiology, QUAL IMPR I
[4]  
American College of Preventive Medicine, MED ADH IMPR HLTH OU
[5]  
American Heart Association, HEART FAIL TOOLS RES
[6]  
[Anonymous], 2015, CORL IV PRESCR INF
[7]  
[Anonymous], PAT CTR MED HOM RES
[8]  
[Anonymous], 2015, ENTR SAC VALS PRESCR
[9]  
Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI [10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000530]
[10]  
Bucci C, 2003, CAN J CARDIOL, V19, P391